StockStory picks Amgen and Medpace as healthcare stocks to watch, brushes off GoodRx

Yahoo Finance··Read original
2▲2 ▼1Impact / 5
Summary · why it matters

StockStory highlights Amgen and Medpace as healthcare stocks with sustainable market-beating potential while recommending investors avoid GoodRx. Amgen, with a market cap of $191.1 billion, posted 12.3% annual revenue growth over two years on a $37.22 billion base and generates strong free cash flow. Medpace, valued at $13.57 billion, achieved 16.9% organic revenue growth and expanded its free cash flow margin by 8.3 percentage points over five years. GoodRx, in contrast, saw flat sales and negative returns on capital, with a revenue base of $787.9 million that lacks scale. Amgen trades at $346.68 per share, Medpace at $513.06, and GoodRx at $2.76.

Impact on assets 3

Biotech & Genomic Medicine▲
Amgen Inc
AMGN
▲ PositiveCapitalrelevance

StockStory highlights Amgen as having sustainable market-beating potential with strong revenue growth and free cash flow.

Medpace Holdings Inc
MEDP
▲ PositiveCapitalrelevance

StockStory highlights Medpace as having sustainable market-beating potential with strong organic revenue growth and expanding free cash flow margin.

Health Care▼
Goodrx Holdings Inc
GDRX
▼ NegativeCapitalrelevance

StockStory recommends avoiding GoodRx due to flat sales, negative returns on capital, and lack of scale.